Showing posts with label Symptomatic NYHA Class II-III Obstructive Hypertrophic Cardiomyopathy. Show all posts
Showing posts with label Symptomatic NYHA Class II-III Obstructive Hypertrophic Cardiomyopathy. Show all posts
Saturday, June 11, 2022

FDA Approves Camzyos (mavacamten) for the Treatment of Symptomatic NYHA Class II-III Obstructive Hypertrophic Cardiomyopathy

›
In continuation of my update on mavacamten Bristol Myers Squibb (NYSE: BMY)  announced  the U.S. Food and Drug Administration (FDA) approval...